An interventional study of LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). and P2Y12 inhibitor-based SAPT after short DAPT in Left Main Coronary Artery Stenosis, sponsored by IGLESIAS Juan Fernando. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by IGLESIAS Juan Fernando · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 42nd largest by planned enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2026, is one of 78 with no phase, reaches primary completion later than 25 of the 40 other live ones, and was the 156th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:
B. Braun Melsungen AG · Sites in Switzerland, Germany
Ages 18+
Translumina GmbH · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
ECRI bv · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 17 · Phase 4 25
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 828 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 296 across the 125 interventional studies, 992 across the 52 observational. Of the 114 that completed or were terminated, 25 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 177 have an industry lead sponsor. The 10 most frequent:
IGLESIAS Juan Fernando is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
IGLESIAS Juan Fernando has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Coronary Artery Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04988685Luzerner KantonsspitalSIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters | 2026-12-31 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06706323Roland von KänelDepressive Symptoms After Cardiac Surgery | 2027-04-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The management of patients with unprotected left main coronary artery (LMCA) disease undergoing percutaneous coronary intervention (PCI) in contemporary interventional cardiology practice remains matter of intense debate. Particularly, the combination of the optimal drug-eluting stent (DES) selection and antiplatelet regimen for patients who require LMCA PCI remains undetermined.
Newer-generation drug-eluting stents with ultrathin-strut metallic platforms have been shown to reduce the risk of target lesion failure compared with thicker-strut drug-eluting stents among all-comer patients undergoing PCI, a difference mainly driven by a lower risk of ischemia-driven target lesion revascularization. In the TALENT prospective, single-blind, multicenter, randomized controlled trial that included 1'435 all-comer patients undergoing PCI, the Supraflex ultrathin-strut biodegradable polymer sirolimus-eluting stent was found non-inferior to the Xience® thin-strut permanent polymer everolimus-eluting stent (Abbott Vascular, USA) with regards to the device-oriented composite clinical endpoint (DoCE), a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization, at 12 months of follow-up. However, the TALENT trial included only 31 (1.5%) lesions located in the left main coronary artery. In the COMPARE 60/80 HBR investigator-initiated, multicenter, prospective randomized trial which included a total of 732 patients at high-bleeding risk undergoing PCI with the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent or the Ultimaster Tansei (Terumo Corp., Tokyo, Japan), the rates of the primary endpoint of the net adverse clinical endpoint, defined as a composite of cardiac death, myocardial infarction, target vessel revascularization, stroke, or BARC 3 or 5 major bleeding events at 12 months were similar in the Supraflex Cruz and the Ultimaster Tansei groups, meeting the prespecified criterion for non-inferiority of the Supraflex Cruz DES compared to the Ultimaster Tansei DES. The safety and efficacy of the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent combined with potent P2Y12 inhibitor aspirin-free SAPT among all-comer patients undergoing PCI for complex coronary lesions, such as patients with LMCA stenosis, have however not been investigated to date.
Recent evidence from a large-scale meta-analysis of several randomized clinical trials including >32'000 patients indicated that 1-3 months of DAPT followed by P2Y12 inhibitor single antiplatelet therapy (SAPT) after second-generation DES implantation was associated with lower risk for major bleeding and similar risk for adverse ischemic outcomes compared with conventional DAPT. These findings suggest that P2Y12 inhibitor SAPT following a short DAPT course (1-3 months) may represent a valuable treatment option for patients undergoing PCI with newer-generation DES compared to standard conventional 12 months DAPT, but this strategy has never been investigated in dedicated randomized clinical trials focused on patients at highest-risk for ischaemic events, such as patients undergoing LMCA PCI.
The ULTIMATE-LM randomized trial aims at filling this current gap of knowledge, which may have large impact on clinical practice and international guidelines. ULTIMATE-LM will be the first randomized clinical trial to investigate the safety and efficacy of a novel ultrathin-strut biodegradable polymer drug-eluting stent (Supraflex Cruz, Sahajanand Medical Technologies Ltd., Surat, India)) combined with P2Y12 inhibitor-based single antiplatelet therapy among patients undergoing PCI for LMCA disease.
Myocardial revascularization for left main coronary artery disease
Significant left main coronary artery disease (LMCA) is observed in 5-7% of patients undergoing coronary angiography. Coronary revascularization for patients with LMCA disease with stenosis >50% and documented ischemia or FFR ≤0.80 for diameter stenosis \<90%, is recommended with a class of recommendation I and level of evidence (LOE) A by the 2018 European Society of Cardiology (ESC) guidelines for myocardial revascularization. However, the optimal management of patients with LMCA disease requiring myocardial revascularization in contemporary clinical practice remains matter of debate.
Coronary artery bypass grafting vs. percutaneous coronary intervention for left main coronary artery disease
The available evidence from randomized controlled trials (RCTs) and meta-analyses comparing coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) using drug-eluting stents (DESs) among patients with LMCA suggests equivalent results for the safety composite of death, myocardial infarction (MI), and stroke up to 5 years of follow-up. A significant interaction with time is notable, providing early benefit for PCI in terms of MI and peri-interventional stroke, which is subsequently offset by a higher risk of spontaneous MI during long-term follow-up. The need for repeat revascularization is higher with PCI than with CABG. The largest RCT among patients with LMCA disease so far performed, EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), compared CABG with PCI using new-generation DESs among 1,905 patients with significant LMCA. At 3 years of follow-up, the primary endpoint of death, stroke, or MI occurred with similar frequency in the CABG and PCI group (14.7% vs. 15.4%; HR 1.00, 95% CI 0.79-1.26, p=0.98). The pre-planned landmark analysis from 30 days to 3 years showed a significant difference for the primary endpoint in favour of CABG (7.9% vs. 11.5%, p=0.02). The NOBLE (Nordic-Baltic-British Left Main Revascularization Study) randomized trial compared CABG with PCI using new-generation biolimus-eluting stents among 1,201 patients with significant LM disease (mean SYNTAX score of 23). At a median follow-up of 3.1 years, the primary endpoint of death, non-procedural MI, stroke, and repeat revascularization occurred more frequently in the PCI than the CABG group (29% vs. 19%; HR 1.48, 95% CI 1.11-1.96, p=0.007). A recent collaborative individual patient data pooled analysis of RCTs including 11,518 patients reviewed the currently available evidence from RCTs comparing CABG with PCI for LMCA or multivessel disease. The primary outcome was all-cause mortality. In the overall cohort, CABG was associated with a significant survival benefit during a mean follow-up of 3.8±1.4 years (5-year all-cause mortality 11.2% after PCI vs. 9.2% after CABG; HR 1.20, 95% CI 1.06-1.37, p=0.0038). There was a linear trend for HRs of death increasing with increasing SYNTAX terciles (p=0.0011 for trend). However, among 4,478 patients with LMCA, those randomly assigned to CABG or PCI with a mean follow-up of 3.4±1.4 years reported similar risks for the primary outcome all-cause mortality (PCI, 10.7% vs. CABG, 10.5%; HR 1.07, 95% CI 0.87-1.33, p=0.52) at 5 years. There were no significant differences in mortality between PCI and CABG in subgroup analyses according to SYNTAX scores. Nevertheless, in patients with a high SYNTAX score, a trend towards better survival was noted with CABG. The proportion of patients with a high SYNTAX score was limited in view of the inclusion criteria of the respective studies. Current evidence indicates that PCI is an appropriate alternative to CABG in LMCA and low-to-intermediate anatomical complexity. Among patients with LMCA and low anatomical complexity, there is evidence that the outcomes with respect to major clinical endpoints are similar for PCI and CABG, resulting in a class I recommendation. Among patients with LMCA and high anatomical complexity, the number of patients studied in RCTs is low due to exclusion criteria; the risk estimates and cIs are imprecise but suggest a trend towards better survival with CABG. Therefore, PCI in this setting cannot be endorsed as reflected by a class III recommendation. For PCI in LMCA with intermediate anatomical complexity, the previous class iIa recommendation was maintained in view of the incomplete 5-year follow-up of the two largest RCTs in this setting.
Percutaneous coronary intervention with drug-eluting stents for left main coronary artery disease
The optimal DES therapy for patients with significant LMCA disease undergoing percutaneous coronary intervention (PCI) in contemporary practice remains undetermined. In the Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions (ISAR-LEFT MAIN-2) (n=650) trial, the cumulative incidence of the primary endpoint, a composite of all-cause death, myocardial infarction, or target lesion revascularization was 17.5% in the thin-strut durable polymer zotarolimus-eluting stent group (Resolute, Medtronic, USA) and 14.3% in the thin-strut biocompatible durable polymer everolimus-eluting stent group (Xience®, Abbott Vascular, USA) (relative risk 1.26; 95% CI]: 0.85 to 1.85; p=0.25) at 12 months. In the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial, the rates of the primary composite endpoint of all-cause death, stroke, or MI, occurred similarly in patients undergoing PCI with the newer-generation thin-strut durable polymer everolimus-eluting stent (Xience®) and coronary artery bypass graft surgery (CABG) (22.0% vs. 19.2%, p=0.13) at 5 years. In the Nordic-Baltic-British left main revascularisation (NOBLE) trial, the rates of the primary composite endpoint of all-cause death, non-procedural MI, any repeat coronary revascularization, and stroke, was 29% in patients undergoing PCI with a thick-strut biodegradable polymer biolimus-eluting stent (Biomatrix Flex®, Biosensors, Switzerland) versus 19% in patients undergoing CABG (HR 1.48, 95% CI 1.11-1.96, CABG significantly better than PCI, p=0.0066) at 5 years. In the Improved Drug Eluting stent for All-comers Left Main (IDEAL-LM) randomized clinical trial, the rate of the primary endpoint, a composite of all-cause death, MI, or clinically indicated target vessel revascularization at 2 years did not differ between patients undergoing PCI with a biodegradable polymer everolimus-eluting stent (Synergy®, Boston Scientific, USA) combined with 4-month Dual Antiplatelet Therapy (DAPT) (14.6%) and those undergoing PCI with a durable polymer everolimus-eluting stent (Xience®, Abbott Vascular, USA) combined with 12-month DAPT (11.4%) (p=0.17). Newer-generation thin-strut polymer-free drug-coated stents have the potential to further mitigate chronic inflammation and promote faster re-endothelialisation. No dedicated randomized clinical trial to date has evaluated the safety and efficacy of newest-generation polymer-free drug-coated stents for PCI in patients with LMCA disease.
Antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease
The 2018 ESC guidelines on myocardial revascularization recommend at least 6 (chronic coronary syndrome) and 12 (acute coronary syndrome) months of DAPT after PCI with newer-generation DES among patients with unprotected LMCA stenosis. However, a recent meta-analysis of five large-scale randomized clinical trials including a total of 32'145 patients, of whom 972 (3%) patients were treated for LMCA disease, indicated that 1-3 months of DAPT followed by P2Y12 inhibitor single antiplatelet therapy (SAPT) after second-generation DES implantation in patients with chronic and acute coronary syndromes was associated with lower risk for major bleeding (random-effects model: HR 0.63, 95% 0.45-0.86) and similar risk for stent thrombosis (random-effects model: HR 1.19, 95% CI 0.86-1.65), all-cause death (random-effects model: HR 0.85, 95% CI 0.70-1.03), MI (random-effects model: HR 1.05, 95% CI 0.89-1.23), and stroke (random-effects model: HR 1.08, 95% CI 0.68-1.74) compared with conventional DAPT. These findings suggest that a potent P2Y12 inhibitor-based SAPT following a short DAPT course (1-3 months) may represent a preferable treatment option, which is associated with similar ischemic, but lower bleeding risk, for patients undergoing PCI with newer-generation DES compared to standard conventional 12 months DAPT. However, the safety and efficacy of a potent P2Y12 receptor inhibitor-based aspirin-free SAPT after complex PCI, such as PCI for LMCA disease, has not been investigated to date.
Newer-generation drug-eluting stents with ultrathin-strut metallic platforms have been shown to reduce the risk of target lesion failure compared with thicker-strut drug-eluting stents among all-comer patients undergoing PCI, a difference mainly driven by a lower risk of ischemia-driven target lesion revascularization. Supraflex Cruz (Sahajanand Medical Technologies Ltd., Surat, India) is a novel newer-generation drug-eluting stent consisting of an L-605 cobalt-chromium alloy metallic stent platform with ultrathin struts (60 μm) across all stent diameters, highly flexible S-link connectors, and a biodegradable polymeric matrix coating (poly L-lactide, 50:50 mixture poly D,L-lactide-co-glycolide and polyvinyl pyrrolidone) eluting sirolimus at a concentration of 1.4 μg/mm2 which is coated on the conformal surface of the stent together with the polymeric matrix. The average thickness of coating ranges from 4 to 5 μm. The drug is 70% released within 7 days, and the remainder is released over a period of 48 days. The polymer gradually degrades over 9-12 months. The proprietary 'LDZ' link design improves stent flexibility, transmits push force with higher efficiency, improves overall radial strength, and resists longitudinal compression. The open-cell design allows for better flexibility and facilitates side branch access. In addition, the 4.0 and 4.5 mm 8-crown stent platforms which allow for an overexpansion capacity up to 5.5 mm facilitates the treatment of patients with large coronary vessels, such as those undergoing LM PCI. In the TALENT prospective, single-blind, multicenter, randomized controlled trial that included 1'435 all-comer patients undergoing PCI, the Supraflex ultrathin-strut biodegradable polymer sirolimus-eluting stent was found non-inferior to the Xience® thin-strut permanent polymer everolimus-eluting stent (Abbott Vascular, USA) with regards to the device-oriented composite clinical endpoint (DoCE), a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization, at 12 months of follow-up. At 3 years, DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (p=0.406). There were no significant between-group differences in rates of cardiac death, target vessel myocardial infarction or clinically indicated target lesion revascularization. The rates of definite or probable stent thrombosis were low and similar between groups (1.1% vs 1.4%; p=0.640). However, the TALENT trial included only 31 (1.5%) lesions located in the left main coronary artery and randomized evidence regarding the safety and efficacy of the Supraflex ultrathin-strut biodegradable polymer sirolimus-eluting stent for PCI in patients with significant LMCA disease remains therefore limited. The TAXCO study investigated the OCT-derived neointimal coverage of the Supraflex Cruz ultrathin-strut biodegradable polymer DES showing that 97.6% of the device struts are endothelialized at 6 months after PCI, which is comparable to the neointimal coverage of the Xience thin-strut everolimus-eluting stent. Equally, no significant difference was found with respect to 6months uncovered and malapposed struts between the 2 devices. Similarly, the SiBi study evaluated the early (4 to 6 weeks) OCT-derived neointimal coverage of the Supraflex Cruz ultrathin-strut biodegradable polymer DES demonstrating an excellent healing profile with a mean of 91.26% strut coverage at 35.3 ± 5 days after the index PCI. Taken together these results indicate an appropriate balance between neointimal thickness and amount of strut coverage that may facilitate short DAPT durations. Particularly, the use of thin strut and ultrathin strut stents may lead to a favorable trade-off in bleeding and ischemic events in patients with high-bleeding risk. In the COMPARE 60/80 HBR investigator-initiated, multicenter, prospective randomized trial which included a total of 732 patients at high-bleeding risk undergoing PCI with the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent or the Ultimaster Tansei (Terumo Corp., Tokyo, Japan), the rates of the primary endpoint of the net adverse clinical endpoint, defined as a composite of cardiac death, myocardial infarction, target vessel revascularization, stroke, or BARC 3 or 5 major bleeding events at 12 months were 15.4% in the Supraflex Cruz group and 17.1% in the Ultimaster Tansei group, meeting the prespecified criterion for non-inferiority of the Supraflex Cruz DES compared to the Ultimaster Tansei DES (p=0.02). The median DAPT duration was 30 (0-181) days. Importantly, a lower rate of target lesion revascularization was observed in the Supraflex Cruz group in comparison to the Ultimaster Tansei group (2.7% vs. 5.3%, p=0.078). Additionally, most other cardiac endpoints showed numerically lower values in the Supraflex Cruz group when compared to the Ultimaster Tansei group. The safety and efficacy of the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India) combined with potent P2Y12 inhibitor aspirin-free SAPT among all-comer patients undergoing PCI for complex coronary lesions, such as patients with LMCA stenosis, have however not been investigated to date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). P2Y12 inhibitor SAPT with any of the commercially available oral P2Y12 inhibitors (ticagrelor, or prasugrel 10 mg) after a short DAPT course during 2 years after the index LMCA procedure. At the discretion of the investigator, aspirin will be discontinued after LMCA PCI, or continued during the hospital stay. In all cases, aspirin will be discontinued at latest at hospital discharge.
Device: LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). · Drug: P2Y12 inhibitor-based SAPT after short DAPT
Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). DAPT combining aspirin and any of the commercially available oral P2Y12 receptor inhibitors (clopidogrel, ticagrelor, or prasugrel) during 6 or 12 months followed by aspirin-based SAPT. In patients with index ACS presentation and who have tolerated DAPT for 12 months without bleeding complications, a prolonged DAPT course with aspirin and ticagrelor 60 mg bd (clopidogrel or prasugrel allowed, if patient not eligible for treatment with ticagrelor) beyond 12 months may be considered in those patients with high thrombotic risk and without an increased risk for major or life-threatening bleeding, and those with moderately elevated thrombotic risk.
Device: LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India). · Drug: Conventional DAPT
Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
Patient-oriented composite endpoint (POCE)
Composite of all-cause death, any non-fatal myocardial infarction, or any revascularization (PCI, or CABG)
Time frame: 2 years
Net adverse clinical and major adverse cardiac (NACE)
Composite of all-cause death, any non-fatal myocardial infarction, any revascularization (PCI, or CABG), or Bleeding Academic Research Consortium (BARC)19 3 or 5 major bleeding
Time frame: 2 years
Device-oriented composite endpoint (DOCE)
Composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization (PCI, or CABG)
Time frame: 2 years
All-cause death
Cardiac and non-cardiac death
Time frame: 2 years
Any non-fatal myocardial infarction
Periprocedural or spontaneous, target vessel-related, and non-target vessel-related myocardial infarction
Time frame: 2 years
Any revascularization
Any revascularization (PCI or CABG)
Time frame: 2 years
Target lesion revascularization
Clinically indicated and non-clinically indicated target lesion revascularization
Time frame: 2 years
Clinically indicated target vessel revascularization
Clinically indicated and non-clinically indicated target vessel revascularization
Time frame: 2 years
Definite stent thrombosis
Academic Research Consortium definite stent thrombosis
Time frame: 2 years
Definite or probable stent thrombosis
Academic Research Consortium definite or probable stent thrombosis
Time frame: 2 years
Bleeding Academic Research Consortium 3 or 5 major bleeding events
BARC 3 or 5 major bleeding complications
Time frame: 2 years
Bleeding Academic Research Consortium ≥2 major bleeding events
BARC ≥2 major bleeding complications
Time frame: 2 years
Plan to share: Yes — Individual participant data will be shared upon reasonable request to the principal investigator after publication of the study primary and secondary endpoints.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After publication of the study primary and secondary endpoints.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 24 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IGLESIAS Juan Fernando